| Literature DB >> 34397707 |
Lingwang An1, Yanlei Wang2, Chenxiang Cao2, Tao Chen3, Yonghong Zhang4, Linhui Chen4, Shuhong Ren5, Manni Tang3, Fenglian Ma5, Xianglan Li1, Shuang Yuan6, Wenhui Zhao2, Yaujiunn Lee7, Jianzhong Xiao2.
Abstract
ABSTRACT: To evaluate the atherosclerotic cardiovascular diseases (ASCVD) risk factors in type 2 diabetes patients from the primary diabetes clinics for further comprehensive intervention in China.A cross-sectional study was conducted in 5 primary diabetes chain hospitals in Beijing, Lanzhou, Harbin, Chengdu, and Taiyuan in continuous patients with type 2 diabetes from March 2016 to December 2019. The data collected at the first visit were analyzed, and proportions of patients reached the targets (glycosylated hemoglobin [HbA1c] < 7%, blood pressure < 130/80 mm Hg, and low-density lipoprotein cholesterol [LDL-C] < 2.6mmol/l) were calculated. The clinical characteristics and the associated factors with achievement in HbA1c, blood pressure, and LDL-C targets were analyzed.A total of 20,412 participants, including 11,353 men (55.6%), with an average age of (59.4 ± 10.4) years were enrolled. Nearly 95% diabetes had one or more ASCVD risk factors other than hyperglycemia. The control rates of HbA1c, blood pressure, and LDL-C were 26.5%, 27.8%, and 42.6%, respectively. Only 4.1% patients achieved all 3 targets. Nearly 95% patients had one or more ASCVD risk factors other than hyperglyciemia. Diabetes duration, family history, and overweight/obesity were associated with the number of aggregated ASCVD risk factors. The patients with older age, no overweight/obesity, not smoking, less ASCVD risk factors, and having special diabetes care insurance (Chengdu) were associated with a higher control rates.To deal with poor control status, global management of ASCVD risk factors, weight loss, and smoking cessation must be emphasized in the primary diabetes care settings. Special diabetes care insurance should be advocated.Current ClinicalTrial.gov protocol ID NCT03707379. Date of Registration: October 16, 2018. https://clinicaltrials.gov.Entities:
Mesh:
Year: 2021 PMID: 34397707 PMCID: PMC8322505 DOI: 10.1097/MD.0000000000026722
Source DB: PubMed Journal: Medicine (Baltimore) ISSN: 0025-7974 Impact factor: 1.817
General characteristic of participants in different clinics.
| Total | Beijing | Lanzhou | Harbin | Chengdu | Taiyuan | ||
| Cases, n | 20,412 | 3047 | 3500 | 7567 | 3251 | 3047 | |
| Age (yrs), mean ± SD | 59.4 ± 10.4 | 57.3 ± 10.8 | 61.0 ± 9.9 | 58.8 ± 10.5 | 61.0 ± 10.0 | 59.3 ± 10.2 | <.001 |
| Gender (male, n [%]) | 11,353 (55.6%) | 1825 (59.9%) | 2037 (58.2%) | 4104 (54.2%) | 1812 (55.7%) | 1575 (51.7%) | <.001 |
| Diabetes duration (yrs), m ± SD | 8.8 ± 6.7 | 9.5 ± 7.4 | 9.1 ± 5.8 | 7.9 ± 6.8 | 9.4 ± 6.3 | 9.4 ± 6.6 | <.001 |
| Education | <.001 | ||||||
| Below high school (n [%]) | 8236 (40.3%) | 1021 (33.5%) | 1684 (48.1%) | 1992 (26.3%) | 1956 (60.2%) | 1583 (52.0%) | |
| High school and advance (n [%]) | 7796 (38.2%) | 1274 (41.8%) | 1587 (45.3%) | 2640 (34.9%) | 1138 (35.0%) | 1157 (38.0%) | |
| Smoking | <.001 | ||||||
| Current (n [%]) | 2339 (11.5%) | 594 (19.5%) | 552 (15.8%) | 290 (3.8%) | 593 (18.2%) | 310 (10.2%) | |
| Past or never (n [%]) | 18,073 (88.5%) | 2453 (80.5%) | 2948 (84.2%) | 7277 (96.2%) | 2658 (81.8%) | 2737 (89.8%) | |
| WC (male, cm) | 91.0 ± 8.8 | 92.1 ± 9.1 | 89.8 ± 8.8 | 92.8 ± 8.7 | 87.6 ± 7.1 | 91.4 ± 9.0 | <.001 |
| WC (female, cm) | 87.3 ± 9.3 | 87.0 ± 9.1 | 87.1 ± 9.6 | 88.5 ± 9.5 | 85.2 ± 7.6 | 87.5 ± 9.6 | <.001 |
| BMI (kg/m2) | 25.2 ± 3.4 | 25.8 ± 3.6 | 24.4 ± 3.1 | 25.6 ± 3.4 | 24.5 ± 3.1 | 25.1 ± 3.4 | <.001 |
| HbA1c (%) | 8.4 ± 2.0 | 8.1 ± 1.9 | 9.0 ± 2.3 | 8.4 ± 1.9 | 7.9 ± 1.9 | 8.7 ± 2.1 | <.001 |
| SBP (mm Hg) | 132.1 ± 18.6 | 131.8 ± 16.8 | 129.3 ± 14.4 | 135.6 ± 20.0 | 127.9 ± 14.2 | 131.4 ± 23.1 | <.001 |
| DBP (mm Hg) | 79.1 ± 10.5 | 80.2 ± 10.0 | 77.2 ± 8.9 | 82.3 ± 11.0 | 74.9 ± 8.5 | 76.6 ± 10.5 | <.001 |
| LDL-C (mmol/l) | 2.76 (2.19–3.36) | 2.95 (2.33–3.60) | 2.61 (2.10–3.22) | 2.83 (2.28–3.40) | 2.66 (2.02–3.29) | 2.66 (2.11–3.24) | <.001 |
| HbA1c < 7% (n [%]) | 5417 (26.5%) | 1015 (33.3%) | 639 (18.3%) | 1915 (25.3%) | 1182 (36.4%) | 666 (21.9%) | <.001 |
| BP < 130/80 mm Hg (n [%]) | 5677 (27.8%) | 777 (25.5%) | 1052 (30.1%) | 1356 (17.9%) | 1486 (45.7%) | 1006 (33.0%) | <.001 |
| LDL-C < 2.6 mmol/l (n,(%)) | 8693 (42.6%) | 1074 (35.2%) | 1721 (49.2%) | 2917 (38.5%) | 1531 (47.1%) | 1450 (47.6%) | <.001 |
| Reaching 2 targets (n [%]) | 4348 (21.3%) | 641 (21.0%) | 734 (21.0%) | 1270 (16.8%) | 991 (30.5%) | 712 (23.4%) | <.001 |
| Reaching 3 targets (n [%]) | 836 (4.1%) | 135 (4.4%) | 131 (3.7%) | 143 (1.9%) | 301 (9.3%) | 126 (4.1%) | <.001 |
Demographics, laboratory results, and control rates of T2DM sample stratified by the number of ASCVD risk factors.
| T2DM only | T2DM with 1 risk factor | T2DM with 2 risk factors | T2DM with more than 3 risk factors | ||
| Cases, n | 1127 | 4383 | 7554 | 7348 | |
| Age (yrs), mean ± SD | 57.9 ± 11.2 | 58.6 ± 10.6 | 59.5 ± 10.5 | 60.0 ± 10.0 | <.001 |
| Age groups | |||||
| ≤50 (n [%]) (n = 3447) | 241 (7.0%) | 845 (24.5%) | 1303 (37.8%) | 1058 (30.7%) | <.001 |
| >50, ≤65 (n [%]) (n = 10,750) | 591 (5.5%) | 2315 (21.5%) | 3890 (36.2%) | 3954 (36.8%) | |
| >65 (n [%]) (n = 6215) | 295 (4.7%) | 1223 (19.7%) | 2361 (38.0%) | 2336 (37.6%) | |
| Gender (male (n [%]) (n = 11,353) | 618 (54.8%) | 2272 (51.8%) | 4094 (54.2%) | 4369 (59.5%) | <.001 |
| Diabetes duration (yrs), m ± SD | 7.9 ± 6.1 | 8.4 ± 6.4 | 8.7 ± 6.7 | 9.2 ± 6.9 | <.001 |
| Diabetes duration groups | <.001 | ||||
| ≤5 (n [%]) (n = 6044) | 364 (6.0%) | 1322 (21.9%) | 2272 (37.6%) | 2086 (34.5%) | |
| >5, ≤10 (n [%]) (n = 4814) | 271 (5.6%) | 1045 (21.7%) | 1794 (37.3%) | 1704 (35.4%) | |
| >10 (n [%]) (n = 7382) | 341 (4.6%) | 1469 (19.9%) | 2684 (36.4%) | 2888 (39.1%) | |
| Education | .23 | ||||
| Below high school (n [%]) (n = 8236) | 448 (5.4%) | 1828 (22.2%) | 3065 (37.2%) | 2895 (35.2%) | |
| High school and above (n [%]) (n = 7796) | 450 (5.8%) | 1680 (21.5%) | 2828 (36.3%) | 2838 (36.4%) | |
| Smoking | <.001 | ||||
| Current (n [%]) (n = 2339) | 0 (0.0%) | 151 (6.5%) | 614 (26.3%) | 1574 (67.3%) | |
| Past or never (%) (n = 18,073) | 1127 (6.2%) | 4232 (23.4%) | 6940 (38.4%) | 5774 (31.9%) | |
| WC (male, cm) | 84.3 ± 7.7 | 87.1 ± 7.8 | 90.7 ± 8.3 | 94.3 ± 8.3 | <.001 |
| WC (female, cm) | 80.2 ± 6.4 | 83.1 ± 7.6 | 87.1 ± 8.7 | 91.8 ± 9.2 | <.001 |
| BMI (kg/m2) | 21.7 ± 1.8 | 23.1 ± 2.8 | 25.0 ± 3.1 | 27.1 ± 2.9 | <.001 |
| Diabetes family history | <.001 | ||||
| Yes (n [%]) (n = 5687) | 238 (4.2%) | 1145 (20.1%) | 2018 (35.5%) | 2286 (40.2%) | |
| No (n [%]) (n = 13,920) | 856 (6.1%) | 3046 (21.9%) | 5200 (37.4%) | 4818 (34.6%) | |
| HbA1c (%) | 8.4 ± 2.3 | 8.5 ± 2.2 | 8.4 ± 2.0 | 8.4 ± 1.8 | .47 |
| FBG (mmol/l) | 9.6 ± 3.9 | 9.8 ± 3.9 | 9.8 ± 3.8 | 9.9 ± 3.7 | .22 |
| SBP (mm Hg) | 119.5 ± 2.3 | 123.6 ± 2.2 | 131.8 ± 2.0 | 139.3 ± 1.8 | <.001 |
| DBP (mm Hg) | 73.2 ± 3.9 | 74.9 ± 3.9 | 78.9 ± 3.8 | 82.7 ± 3.7 | <.001 |
| Total cholesterol (mmol/l) | 4.17 (3.70–4.64) | 4.74 (4.05–5.56) | 5.00 (4.28–5.80) | 5.20 (4.44–5.96) | <.001 |
| LDL-C (mmol/l) | 2.11 (1.77–2.35) | 2.50 (2.04–3.14) | 2.79 (2.22–3.37) | 3.01 (2.51–3.55) | <.001 |
| Triglyceride (mmol/l) | 1.20 (0.90–1.70) | 1.45 (1.05–2.10) | 1.66 (1.20–2.40) | 1.87 (1.34–2.67) | <.001 |
| HbA1c < 7% (n [%]) | 349 (31.0%) | 1283 (29.3%) | 2001 (26.5%) | 1784 (24.3%) | <.001 |
| BP < 130/80 mm Hg (n [%]) | 591 (52.4%) | 1966 (44.9%) | 2067 (27.4%) | 1053 (14.3%) | <.001 |
| LDL-C < 2.6 mmol/l (n [%]) | 1127 (100.0%) | 2455 (56.0%) | 3109 (41.2%) | 2002 (27.2%) | <.001 |
| Reached 3 targets (n [%]) | 195 (17.3%) | 329 (7.5%) | 206 (2.7%) | 106 (1.4%) | <.001 |
The patient number reached goal and control rates stratified by treatment (n [%]).
| Total | Non-insulin | Insulin | Non-antihypertensive | Antihypertensive | Non-lipid lowering | Lipid lowering | |
| HbA1c < 7% | 5417 (26.5%) | 3896 (33.1%) | 1521 (17.6%)∗∗ | 3958 (25.9%) | 1459 (28.4%)∗∗ | 4080 (26.6%) | 1337 (26.3%) |
| BP < 130/80 mm Hg | 5677 (27.8%) | 3350 (28.5%) | 2327 (26.9%)∗ | 4606 (30.1%) | 1071 (20.9%)∗∗ | 4337 (28.3%) | 1340 (26.3%)∗∗ |
| LDL-C < 2.6 mmol/L | 8693 (42.6%) | 5008 (42.5%) | 3685 (42.7%) | 6350 (41.6%) | 2343 (45.7%)∗∗ | 6707 (43.8%) | 1986 (39.0%)∗∗ |
| Reached 3 targets | 836 (4.1%) | 627 (5.3%) | 209 (2.4%)∗∗ | 660 (4.3%) | 176 (3.4%)∗∗ | 656 (4.3%) | 180 (3.5%)∗ |
The patient number reached goal and control rates stratified by age, gender, and diabetes duration (n [%]).
| BP < 130/80 mm Hg | HbA1c < 7% | LDL-C < 2.6 mmol/l | Reaching 3 goals | |
| Age (yrs) | ||||
| ≤50 | 1133 (32.9%) | 1449 (42.0%) | 732 (21.2%) | 124 (3.6%) |
| >50, ≤65 | 3031 (28.2%) | 4453 (41.4%) | 2884 (26.8%) | 442 (4.1%) |
| >65 | 1513 (24.3%) | 2791 (44.9%) | 1801 (29.0%) | 270 (4.3%) |
| | <.001 | <.001 | <.001 | .21 |
| Sex | ||||
| Male | 3031 (26.7%) | 5222 (46.0%) | 2968 (26.1%) | 453 (4.0%) |
| Female | 2646 (29.2%) | 3471 (38.3%) | 2449 (27.0%) | 383 (4.2%) |
| | <.001 | .15 | <.001 | .40 |
| Diabetes duration (yrs) | ||||
| <1 | 586 (30.0%) | 726 (37.1%) | 555 (28.4%) | 67 (3.4%) |
| ≥1, <5 | 1158 (28.4%) | 1686 (41.3%) | 1336 (32.7%) | 184 (4.5%) |
| ≥5, <10 | 1420 (29.5%) | 2099 (43.6%) | 1289 (26.8%) | 221 (4.6%) |
| ≥10 | 1970 (26.7%) | 3245 (43.9%) | 1675 (22.7%) | 299 (4.0%) |
| | .001 | <.001 | <.001 | .11 |
Associated factors of patients reaching all 3 ABC targets.
| Potential predictor | Univariate regression | Multivariate regression | Multivariate regression adjusted∗ | |||
| OR (95% CI) | OR (95% CI) | OR (95% CI) | ||||
| Age (every 10 yrs increase) | 1.07 (1.00–1.14) | .06 | 1.12 (1.04–1.21) | .003 | 1.11 (1.02–1.21) | .01 |
| Gender (male vs female) | 0.94 (0.82–1.08) | .40 | 0.92 (0.77–1.09) | .32 | ||
| Diabetes duration (every 2 yrs increase) | 0.98 (0.90–1.07) | .71 | 1.04 (0.93–1.15) | .51 | ||
| Education (high school or above vs below high school) | 0.91 (0.78–1.06) | .22 | 1.13 (0.96–1.32) | .15 | 1.18 (0.99–1.40) | .06 |
| BMI (≥24 kg/m2 vs | 0.60 (0.52–0.69) | <.001 | 0.75 (0.64–0.88) | <.001 | 0.77 (0.65–0.91) | .002 |
| Current smoking vs non-smoking and withdrawal | 0.99 (0.80–1.23) | .93 | 0.72 (0.56–0.94) | .02 | ||
| Clinic in other cities vs clinic in Harbin | ||||||
| Beijing | 1.10 (0.91–1.33) | .31 | 3.26 (2.42–4.41) | <.001 | 3.74 (2.72–5.14) | <.001 |
| Lanzhou | 0.89 (0.74–1.08) | .25 | 1.35 (1.02–1.78) | .04 | 1.64 (1.21–2.22) | .001 |
| Chengdu | 3.17 (2.74–3.67) | <.001 | 5.43 (4.24–6.95) | <.001 | 6.18 (4.73–8.08) | <.001 |
| Taiyuan | 1.01 (0.83–1.23) | .91 | 2.60 (1.96–3.46) | <.001 | 2.82 (2.07–3.83) | <.001 |
| Insulin therapy vs OAD or TLC | 0.44 (0.38–0.52) | <.001 | 0.42 (0.35–0.51) | <.001 | 0.41 (0.34–0.50) | <.001 |
| History of hypertension (yes vs no) | 0.53 (0.46–0.61) | <.001 | 0.65 (0.54–0.77) | <.001 | 0.64 (0.53–0.76) | <.001 |
| History of hyperlipidemia (yes vs no) | 0.18 (0.15–0.20) | <.001 | 0.17 (0.14–0.20) | <.001 | 0.17 (0.14–0.20) | <.001 |
Results of individual or combined treatment goals achieved for the T2DM patients in different studies and also stratified according to sex and age.
| Studies | BP < 130/80 mm Hg (%) | HbA1c < 7% (%) | LDL-C < 2.6 mmol/l (%) | BP < 130/80 mm Hg, HbA1c < 7%, and LDL-C < 2.6 mmol/l (%) | BP < 140/90 mm Hg (%) | BP < 140/90 mm Hg, HbA1c < 7%, and LDL-C < 2.6 mmol/l (%) | Study design |
| Xu[ | 39.7 | A national wide, complex, multistage, probability sampling design | |||||
| Gao[ | 36.7 | National wide, community-based study | |||||
| Ji[ | 28.4 | 47.7 | 42.9 | 5.6 | Patients from endocrinology, cardiology, nephrology, and internal medicine clinics in Tier 1–3 hospitals | ||
| Lv[ | Newly diagnosed T2DM patients from Tier 1–3 hospitals | ||||||
| <65 | 33.5 | 37 | 44.3 | 11.1 | |||
| ≥65 | 47.8 | 39.4 | 44.9 | 13.5 | |||
| Xu[ | 25.9 | 4.5 | 6 tertiary hospitals across Shaanxi province | ||||
| Vinagre[ | 31.7 | 56.1 | 37.9 | 12.1 | All patients with T2DM treated at the Catalan Health Institute, who were nearly free of charge | ||
| <65 | 33.3 | 51.8 | 32.8 | 11.9 | |||
| ≥65 | 30.9 | 58.5 | 40.6 | 12.1 | |||
| Male | 32 | 55.8 | 41.3 | 13.3 | |||
| Female | 31.4 | 56.5 | 34.2 | 9.9 | |||
| Braga[ | 54 | 53 | 64 | 21 | Primary care physicians were instructed to enroll T2DM patients | ||
| Wong ND[ | 34.2–52.8 | 35–55.5 | 37–54.4 | 2.5–24.9 | NHANES 1999–2010 | ||
| Our study | 27.8 | 26.5 | 42.6 | 4.1 | 60.9 | 8.5 | |
| <65 | 29.3 | 25.5 | 41.6 | 4 | 63.4 | 8.4 | |
| ≥65 | 24.3 | 29 | 44.9 | 4.3 | 55.3 | 8.9 | |
| Male | 26.7 | 26.1 | 46 | 4 | |||
| Female | 29.2 | 27 | 38.3 | 4.2 |
General characteristic and control rates of participants stratified by different age groups.
| Age (yrs) | 18–53.5 (n = 5103) | 53.6–60.4 (n = 5103) | 60.5–66.4 (n = 5105) | 66.4–80 (n = 5101) | |
| Gender (male, n [%]) | 3384 (66.3%) | 2811 (55.1%) | 2717 (53.2%) | 2441 (47.9%) | <.001 |
| Diabetes duration (yrs), m ± SD | 5.9 ± 4.9 | 8.2 ± 6.1 | 9.6 ± 6.6 | 11.5 ± 7.5 | <.001 |
| Education | <.001 | ||||
| Below high school (n [%]) | 1499 (18.2%) | 1833 (22.3%) | 2320 (28.2%) | 2584 (31.4%) | |
| High school and above (n [%]) | 2430 (31.2%) | 2108 (27.0%) | 1706 (21.9%) | 1552 (19.9%) | |
| Smoking | <.001 | ||||
| Current (n [%]) | 838 (35.8%) | 626 (26.8%) | 537 (23.0%) | 338 (14.5%) | |
| Past or never (%) | 4265 (23.6%) | 4477 (24.8%) | 4568 (25.3%) | 4763 (26.4%) | |
| WC (cm) | 89.3 ± 9.6 | 89.2 ± 8.9 | 89.4 ± 9.1 | 89.4 ± 9.1 | .76 |
| BMI (kg/m2) | 25.5 ± 3.7 | 25.2 ± 3.3 | 25.1 ± 3.3 | 25.0 ± 3.2 | <.001 |
| Diabetes family history | <.001 | ||||
| Yes (n [%]) | 1708 (30.0%) | 1546 (27.2%) | 1416 (24.9%) | 1017 (17.9%) | |
| No (n [%]) | 3237 (23.3%) | 3344 (24.0%) | 3470 (24.9%) | 3869 (27.8%) | |
| HbA1c < 7% (n [%]) | 1145 (22.4%) | 1308 (25.6%) | 1509 (29.6%) | 1455 (28.5%) | <.001 |
| BP < 130/80 mm Hg (n [%]) | 1618 (31.7%) | 1491 (29.2%) | 1324 (25.9%) | 1244 (24.4%) | <.001 |
| LDL-C < 2.6 mmol/l (n [%]) | 2134 (41.8%) | 2097 (41.1%) | 2147 (42.1%) | 2315 (45.4%) | <.001 |
| Reaching 3 targets (n [%]) | 193 (3.8%) | 207 (4.1%) | 213 (4.2%) | 223 (4.4%) | .50 |
General characteristics of participants in different clinics stratified by numbers of ABC targets reached.
| Total | Could not reach any target | Reaching 1 target | Reaching 2 targets | Reaching 3 targets | ||
| Cases (n [%]) | 20,412 (100.0%) | 6645 (32.6%) | 8583 (42.0%) | 4348 (21.3%) | 836 (4.1%) | |
| Age (yrs), mean ± SD | 59.4 ± 10.4 | 59.2 ± 10.5 | 59.5 ± 10.4 | 59.4 ± 10.3 | 60.1 ± 10.0 | .066 |
| Gender (male, n [%]) | 11,353 (55.6%) | 3523 (53.0%) | 4892 (57.0%) | 2485 (57.2%) | 453 (54.2%) | <.001 |
| Diabetes duration (yrs), m ± SD | 8.8 ± 6.7 | 9.0 ± 6.7 | 8.9 ± 6.8 | 8.3 ± 6.5 | 8.5 ± 6.4 | <.001 |
| Education | .33 | |||||
| Below high school (n [%]) | 8236 (40.3%) | 2524 (38.0%) | 3502 (40.8%) | 1827 (42.0%) | 383 (45.8%) | |
| High school and advance (n [%]) | 7796 (38.2%) | 2470 (37.2%) | 3256 (37.9%) | 1739 (40.0%) | 331 (39.6%) | |
| Current smoking (female, n [%]) | 146 (1.6%) | 50 (1.6%) | 55 (1.5%) | 38 (2.0%) | 3 (0.8%) | .24 |
| Past smoking (female, n [%]) | 24 (0.3%) | 4 (0.1%) | 12 (0.3%) | 6 (0.3%) | 2 (0.5%) | |
| Current smoking (male, n [%]) | 2193 (19.3%) | 667 (18.9%) | 935 (19.1%) | 499 (20.1%) | 92 (20.3%) | .87 |
| Past smoking (male, n [%]) | 365 (3.2%) | 108 (3.1%) | 149 (3.0%) | 92 (3.7%) | 16 (3.5%) | |
| WC (male, cm) | 91.0 ± 8.8 | 92.2 ± 8.6 | 91.3 ± 8.8 | 89.4 ± 8.7 | 87.7 ± 8.0 | <.001 |
| WC (female, cm) | 87.3 ± 9.3 | 88.7 ± 9.3 | 87.4 ± 9.3 | 85.7 ± 8.9 | 83.7 ± 7.5 | <.001 |
| BMI (male, kg/m2) | 25.3 ± 3.2 | 25.7 ± 3.3 | 25.3 ± 3.2 | 24.8 ± 3.1 | 24.2 ± 2.9 | <.001 |
| BMI (female, kg/m2) | 25.1 ± 3.6 | 25.6 ± 3.6 | 25.1 ± 3.6 | 24.6 ± 3.5 | 24.0 ± 3.2 | .017 |
| HbA1c (%) | 8.4 ± 2.0 | 9.2 ± 1.8 | 8.5 ± 2.0 | 7.5 ± 2.0 | 6.2 ± 0.5 | <.001 |
| SBP (mm Hg) | 132.1 ± 18.6 | 139.2 ± 20.2 | 132.1 ± 16.9 | 124.1 ± 15.3 | 116.0 ± 8.6 | <.001 |
| DBP (mm Hg) | 79.1 ± 10.5 | 83.5 ± 9.6 | 79.1 ± 10.3 | 74.2 ± 9.3 | 69.1 ± 5.7 | <.001 |
| LDL-C (mmol/l) | 2.76 (2.19–3.36) | 3.29 (2.94–3.81) | 2.58 (2.10–3.21) | 2.21 (1.83–2.53) | 2.01 (1.63–2.33) | <.001 |
| HbA1c < 7% (n [%]) | 5417 (26.5%) | 0 (0.0%) | 1974 (23.0%) | 2607 (60.0%) | 836 (100.0%) | <.001 |
| BP < 130/80 mm Hg (n [%]) | 5677 (27.8%) | 0 (0.0%) | 2250 (26.2%) | 2591 (59.6%) | 836 (100.0%) | <.001 |
| LDL-C < 2.6 mmol/l (n [%]) | 8693 (42.6%) | 0 (0.0%) | 4359 (50.8%) | 3498 (80.5%) | 836 (100.0%) | <.001 |
Numbers of ASCVD risk factors and individual or combined treatment goals achieved for the T2DM patients in different studies and also stratified according to educational level.
| Studies | Total | T2DM only (%) | T2DM with 1 risk factor (%) | T2DM with 2 risk factors (%) | T2DM with 3 risk factors and more (%) | BP < 140/80 mm Hg (%) | HbA1c < 7% (%) | Total serum cholesterol <4.5 mmol/l (%) | Reached 3 targets (%) |
| Gao N[ | 36.7 | ||||||||
| Less than secondary | 3256 (63.5%) | 10.2 | 35.4 | 43.9 | 10.6 | ||||
| Secondary | 1323 (25.8%) | 13.4 | 35.5 | 39.6 | 11.5 | ||||
| Postsecondary | 547 (10.7%) | 11.9 | 37.1 | 40.2 | 10.8 | ||||
| Tao X (CCMR-3B)[ | |||||||||
| Illiteracy | 1695 (6.7%) | ∼7.1 | |||||||
| Primary education | 5667 (22.3%) | ∼7.5 | |||||||
| Secondary education | 11,936 (46.9%) | ∼7.5 | |||||||
| College and above | 6156 (24.2%) | 9 | |||||||
| Our study | 5.6 | 21.9 | 36.8 | 35.7 | 39.2 | 27.1 | 34.2 | 5.1 | |
| Less than secondary | 1999 (12.5%) | 5.7 | 23.3 | 39 | 32.1 | 45.1 | 23.1 | 37.2 | 5.7 |
| Secondary | 12,325 (76.9%) | 5.6 | 21.9 | 36.6 | 35.9 | 38.3 | 27 | 33.3 | 4.8 |
| Postsecondary | 1708 (10.7%) | 5.5 | 20.4 | 35.1 | 39 | 38.8 | 32.8 | 36.8 | 6 |